EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Mogamulizumab‐associated rash – Case series and review of the literature

Inga Hansen, Finn Abeck iD, Anne Menz, Stefan W Schneider, Nina Booken

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2024

DOI: 10.1111/ddg.15432 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2024. Verfasst von Inga Hansen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Skin Neoplasms, Exanthema. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mogamulizumab, a monoclonal antibody directed against CC chemokine receptor 4, is approved as a second‐line treatment of mycosis fungoides and Sézary syndrome. One of the most common side effects is mogamulizumab‐associated rash (MAR), which can present in a variety of clinical and histological types. Clinically, it can be difficult to differentiate between MAR and progression of the underlying disease, so histological examination is crucial for clinicopathological correlation. Current data analyses suggest that MAR is more common in patients with Sézary syndrome and is associated with a significantly better response to treatment, making the distinction from disease progression particularly important. The management of MAR depends on its severity, and therapy may need to be paused. This article presents three cases from our clinic and reviews the current literature on MAR. It emphasizes the importance of understanding MAR in the management of patients with cutaneous lymphomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedSkin NeoplasmsExanthemaHumansMaleFemaleAgedMiddle AgedDrug EruptionsSezary Syndrome

Stichwörter der Autor:innen

cutaneous t cell lymphomamogamulizumabmogamulizumab-associated rashmycosis fungoidessézary syndrome

Substanzen

mogamulizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

ORCID-Profile: Finn Abeck

Zitieren

APA

Hansen, I., Abeck, F., Menz, A., Schneider, S. W., & Booken, N. (2024). Mogamulizumab‐associated rash – Case series and review of the literature. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15432

Vancouver

Hansen I, Abeck F, Menz A, Schneider SW, Booken N. Mogamulizumab‐associated rash – Case series and review of the literature. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2024. doi:10.1111/ddg.15432

BibTeX
@article{Hansen2024,
  author = {Hansen, Inga and Abeck, Finn and Menz, Anne and Schneider, Stefan W and Booken, Nina},
  title = {Mogamulizumab‐associated rash – Case series and review of the literature},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2024},
  doi = {10.1111/ddg.15432}
}
Kostenlos starten →